By Dr. Mats Lundgren,GE Healthcare Life Sciences
By recognizing the limitations of today’s production processes, the industry may be able to overcome the challenges, complexity, and high cost of manufacturing vaccines and viral vector-based therapies.
White Paper |
By B. Rosenblatt, Ph.D., SME Biotech Consulting and D. Kenyon, Ph.D., Patheon
Biopharmaceutical executives must consider how outsourcing fits into their development and production strategy, as well as how to select the best CDMO partner for their business. Here’s a step-by-step guide to help make that decision.